PROVIDER PROFILE · NPI 1326057449

Rashel GoodkinMD

PRACTICEDERMATOLOGY & SKIN CARE ASSOC PCSee all providers at this practice →

DermatologyWellesley, MAI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

1,311

Unique beneficiaries

—

Total services

1,941

Distinct HCPCS

Medicare payment

$115K

Peer benchmark

Total Medicare services vs. 478 Dermatology providers in MA — above median (cohort median 1,835).

PRESCRIBING · PART D · 2024

Total Rx claims

1,079

Beneficiaries

—

Total drug cost

$377K

Distinct drugs

Brand share

9.0%

Top prescribed drugs

Ketoconazole292 claims

Tacrolimus93 claims

Triamcinolone Acetonide92 claims

Betamethasone Valerate86 claims

Fluorouracil74 claims

QUALITY · MIPS · 2024

No data available for this provider in 2024.

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$177

Payment records

By payment type

Food and Beverage$177

FACILITY AFFILIATIONS

Hospital & Facility Affiliations (1)

CCN 220101

Hospital

REFERRAL NETWORK

Where Rashel Goodkin's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 1 inbound referrers · 5 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Scott Wenson Pathology · Boston, MA	61	125

Refers patients to

Outbound — where patients go next

Physician	Patients	Visits
NEWTON-WELLESLEY HOSPITAL	64	162
Seacoast Pathology Inc Clinical Laboratory · Exeter, NH	60	110
Scott Wenson Pathology · Boston, MA	18	32
Anne Laraia Dermatology · Arlington, MA	13	62
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	13	21

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history